Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer

NCT01644968 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Advanced Cancer

Interventions

DRUG: Cohort 1 anti-OX40
DRUG: Cohort 2 anti-OX40
DRUG: Cohort 3 anti-OX40
BIOLOGICAL: Tetanus Day 29
BIOLOGICAL: Tetanus Day 1
BIOLOGICAL: KLH Day 1
BIOLOGICAL: KLH Day 29

Sponsor

Providence Health & Services